Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AnGes, Inc.
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.
A clutch of Chinese biopharma firms, including I-Mab, Lepu and Clover, are having second thoughts on some of their clinical development programs to conserve cash amid a funding squeeze.
After five state-owned US-listed Chinese firms announce plans to delist from the US stock market, private firms such as Alibaba follow the lead.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- AnGes Co., Ltd.
- AnGes MG
- EmendoBio Inc.
- Emendo Biotherapeutics